Cipla vs Lupin: Which Stock Should You Track
- July 31, 2026
- Posted by: Ankit Jaiswal
- Category: News
Cipla vs Lupin: a leading Indian pharmaceutical company with respiratory category leadership vs a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Cipla sector: Pha…
Cipla vs Lupin is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Cipla vs Lupin breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Cipla vs Lupin this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.
Cipla vs Lupin: Reach and Market Position
In the Cipla vs Lupin comparison, Cipla stands out for a leading Indian pharmaceutical company with a strong respiratory and India-business franchise, maintaining a net cash position of over Rs 9,000 crore. This scale gives Cipla a distinct position within Pharmaceuticals that shapes how it competes.
Click Here – Get Free Investment Predictions
Lupin, on the other hand, is built around a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascular and anti-diabetic therapies across India, the US and other global markets. Comparing Cipla vs Lupin on reach alone shows two different growth strategies, not a single verdict.
Cipla vs Lupin: Key Products and Business Mix
Cipla’s business runs on respiratory therapies, generic drugs, oncology treatments, and One India branded formulations. This product mix is central to any Cipla vs Lupin comparison, since it explains where each company’s revenue actually comes from.
Lupin instead leans on generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas. The Cipla vs Lupin product comparison shows these are genuinely different businesses, not just different brand names in the same category.
Cipla vs Lupin: Latest Results
Looking at real numbers rather than claims, Cipla’s latest disclosed results show Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contraction and new labour-code-related costs even as India business revenue hit a record Rs 3,452 crore; FY26 revenue was a record Rs 28,000 crore. This is the clearest evidence available for the Cipla vs Lupin comparison on Cipla’s side.
Lupin’s latest disclosed results show Positioned by the market among India’s larger generics exporters, with growth tied to US generic approvals and India branded formulation sales. Weighing Cipla vs Lupin on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.
Compare Cipla and Lupin Fundamentals on the Univest Screener
Cipla vs Lupin: Stock and Valuation
On the market side, Cipla is described as: Maintained a strong net cash position despite the profit decline. Lupin is described as: Tracked alongside Sun Pharma, Dr Reddy’s, Cipla and Aurobindo Pharma as one of India’s major listed pharma companies. The Cipla vs Lupin valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.
Cipla vs Lupin: Quick Comparison Table
| Parameter | Cipla | Lupin |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market position | a leading Indian pharmaceutical company with respiratory category leadership | a leading Indian pharmaceutical company in respiratory and cardiovascular generics |
| Reach | a leading Indian pharmaceutical company with a strong respiratory and India-business franc | a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascula |
| Latest results | Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, wi | Positioned by the market among India’s larger generics exporters, with growth tied to US generic app |
Conclusion
Cipla vs Lupin ultimately comes down to two companies solving similar problems in different ways. Cipla brings a leading Indian pharmaceutical company with respiratory category leadership, while Lupin brings a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Investors weighing Cipla vs Lupin should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Cipla vs Lupin breakdown is a starting point, not a final verdict.
Download the Univest iOS App or Univest Android App to track Cipla and Lupin live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the main difference between Cipla and Lupin?
Ans. The main difference in the Cipla vs Lupin comparison lies in scale and business mix. Cipla is built on a leading Indian pharmaceutical company with respiratory category leadership, while Lupin is positioned around a leading Indian pharmaceutical company in respiratory and cardiovascular generics.
How do Cipla and Lupin’s latest results compare?
Ans. Comparing Cipla vs Lupin on latest disclosed results: Cipla reported Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contract, while Lupin reported Positioned by the market among India’s larger generics exporters, with growth tied to US generic approvals and India branded formulation sal.
What sector do Cipla and Lupin operate in?
Ans. Cipla operates in Pharmaceuticals and Lupin operates in Pharmaceuticals. Even where the sectors overlap, the Cipla vs Lupin comparison shows different product mixes and market positions.
Should I invest in Cipla or Lupin?
Ans. Both Cipla and Lupin have distinct strengths within their space. Investors comparing Cipla vs Lupin should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.
What are the key products of Cipla?
Ans. Cipla’s key products and business lines include respiratory therapies, generic drugs, oncology treatments, and One India branded formulations.
What are the key products of Lupin?
Ans. Lupin’s key products and business lines include generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas.
How do Cipla and Lupin compare on market position?
Ans. On market position, Cipla holds a leading Indian pharmaceutical company with respiratory category leadership, while Lupin holds a leading Indian pharmaceutical company in respiratory and cardiovascular generics. The Cipla vs Lupin comparison shows both companies lead in different ways rather than one being universally ahead.
